Cargando…

Ponatinib vs. Imatinib as Frontline Treatment for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Matching Adjusted Indirect Comparison

INTRODUCTION: Efficacy of ponatinib-based treatment for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) has not been compared to imatinib-based treatments in head-to-head clinical trials. We evaluated its efficacy versus imatinib-based regimens using a matching...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ribera, Josep-Maria, Prawitz, Thibaud, Freitag, Andreas, Sharma, Anuj, Dobi, Balázs, Rizzo, Federica, Sabatelli, Lorenzo, Patos, Petros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272268/ https://www.ncbi.nlm.nih.gov/pubmed/37208556 http://dx.doi.org/10.1007/s12325-023-02497-y

Ejemplares similares

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome–positive acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2022)

Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison
por: Cordoba, Raul, et al.
Publicado: (2022)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

Monitoring Ponatinib in a Child with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Tanimura, Kazuki, et al.
Publicado: (2021)

Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia
por: Niswander, Lisa M., et al.
Publicado: (2021)

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph(+) acute lymphoblastic leukemia
por: Martinelli, Giovanni, et al.
Publicado: (2022)

Imatinib Treatment Alone in Philadelphia-Positive Acute Lymphoblastic Leukemia: Is It Enough?
por: Ay, Yilmaz, et al.
Publicado: (2010)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou, Theodora, et al.
Publicado: (2017)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives [Erratum]
Publicado: (2018)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
por: Niyongere, Sandrine, et al.
Publicado: (2020)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study
por: Zhu, Yuanxin, et al.
Publicado: (2023)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

The role of stem cell transplantation in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ribera, Jose-Maria, et al.
Publicado: (2018)

Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter
por: Ribera, Josep-Maria
Publicado: (2021)

The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
por: Pouwer, Marianne G., et al.
Publicado: (2018)

S110: PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL
por: Jabbour, Elias, et al.
Publicado: (2023)

Efficacy of Inotuzumab Ozogamicin plus Ponatinib Followed by Allogeneic Stem Cell Transplantation in a Patient with Relapsed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
por: Micheva, Ilina, et al.
Publicado: (2021)

Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
por: Price, Kimberly E, et al.
Publicado: (2013)

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
por: Tusa, Ignazia, et al.
Publicado: (2020)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report and literature review
por: ZHANG, LI, et al.
Publicado: (2015)

Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China
por: Cao, Wang, et al.
Publicado: (2022)

Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia
por: Wang, Huafeng, et al.
Publicado: (2022)

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome‐positive leukemias with the T315I mutation
por: Nicolini, Franck E., et al.
Publicado: (2017)

P394: FRONTLINE COMBINATION OF OLVEREMBATINIB AND PDT-ALL-2016 PEDIATRIC INSPIRED PROTOCOL IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Zhu, Kaibo, et al.
Publicado: (2023)

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION
por: Gore, L., et al.
Publicado: (2022)

P379: PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
por: Haddad, Fadi, et al.
Publicado: (2023)

Philadelphia chromosome-positive B-lymphoblastic lymphoma successfully treated with chemotherapy regimen containing imatinib: A rare case report and literature review
por: Li, Xiaoning, et al.
Publicado: (2021)

Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
por: Singh, Surjit, et al.
Publicado: (2016)

Favorable outcome of allogeneic hematopoietic stem cell transplantation followed by post-transplant treatment with imatinib in children with Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Byun, Ye Jee, et al.
Publicado: (2015)

Outcome and prognostic factors of children with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib followed by allogeneic hematopoietic cell transplantation in first remission
por: Shin, Juae, et al.
Publicado: (2019)

Tanshinone IIA potentiates the efficacy of imatinib by regulating the AKT-MDM2-P53 signaling pathway in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Guo, Yong, et al.
Publicado: (2022)

Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China
por: Chen, Min, et al.
Publicado: (2023)

Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice—data from a Belgian registry
por: Devos, Timothy, et al.
Publicado: (2021)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
por: Giudice, Valentina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_053vv9fui5090du48r3ol6paj2